Large gap with delayed quotes
|
Last quote
07/03/2025
-
16:24:43
|
Bid
07/03/2025 -
16:25:09
|
Bid Volume |
Ask
07/03/2025 -
16:25:09
|
Ask Volume |
|---|---|---|---|---|
|
18.15
-0.045
(
-0.25% )
|
18.13
|
200 |
18.17
|
100 |
Analysis date: 01.07.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 01.07.2025.
Interest
Weak
Weak
Two stars since 24.06.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 04.03.2025 at a price of 102.86.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The stock appears oversold from a technical perspective due to its recent losses. It trades below its forty day technical trend since 14.01.2025.
4wk Rel Perf
-57.49%
-57.49%
The stock appears oversold from a technical perspective, with a four week dividend-adjusted underperformance of of 57.49% behind the SP500.
Sensibility
High
High
The stock has been on the high-sensitivity level since 07.02.2025.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.75%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 5.94%.
Mkt Cap in $bn
1.68
1.68
With a market capitalization <$2bn, SAREPTA THERAPEUTICS is considered a small-cap stock.
G/PE Ratio
0.50
0.50
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
290.95
290.95
The estimated PE is for the year 2028.
LT Growth
144.09%
144.09%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
17
17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
77
77
For 1% of index variation, the stock varies on average by 0.77%.
Correlation
0.22
0.22
Stock movements are strongly independent of index variations.
Value at Risk
4.25
4.25
The value at risk is estimated at USD 4.25. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2013
21.05.2013